Skip to main content

Drug Interactions between coccidioidin skin test and ketoconazole

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

ketoconazole coccidioidin skin test

Applies to: ketoconazole and coccidioidin skin test

MONITOR: Antifungal medications may interfere with delayed-type hypersensitivity responses to the coccidioidin skin test in patients with a history of pulmonary coccidioidomycosis, potentially resulting in incorrect results. The mechanism of this theoretical interaction is not described in the package labeling, but may involve the ability of antifungal agents to modify cellular functions of the immune system, potentially affecting the patient's delayed-type hypersensitivity reaction to the coccidioidin skin test. Clinical data are limited and conflicting. Receipt of concurrent or previous systemic antifungal therapy did not appear to interfere with or accentuate the induration response to the coccidioidin skin test, according to data obtained from a study in healthy adult subjects who had recently recovered from acute primary pulmonary coccidioidomycosis in Bakersfield, CA and Tucson, AZ. In contrast, a different small study at the Southern Arizona Veterans Affairs Health Care System of subjects with non-meningeal coccidioidomycosis identified receipt of antifungal medication as a factor related to a failure to express delayed-type hypersensitivity to the coccidioidin skin test. However, the authors of this study suggest that factors such as receipt of antifungal medication may be indicators of patients with less intact immunity or more severe coccidioidomycosis and perhaps that is the reason that these patients did not express delayed-type hypersensitivity to the skin test.

MANAGEMENT: Until more data are available, caution may be advisable if use of the coccidioidin skin test is being considered in a patient with a history of pulmonary coccidioidomycosis who is also on systemic antifungal medication(s). Clinicians should be aware of the potential for interference with delayed-type hypersensitivity responses in patients on concomitant antifungal agents.

References (8)
  1. (2023) "Product Information. Spherusol (coccidioidin skin test)." Nielsen Biosciences Inc
  2. Pawelec G, Ehninger G, Rehbein A, Schaudt K, Jaschonek K (1991) "Comparison of the immunosuppressive activities of the antimycotic agents itraconazole, fluconazole, ketoconazole and miconazole on human T-cells." Int J Immunopharmacol, 13, p. 299-304
  3. Johnson R, Kernerman SM, Rastogi SC, Nielsen HS, Ampel NM, Sawtelle BG (2012) "A reformulated spherule-derived coccidioidin (Spherusol) to detect delayed-type hypersensitivity in coccidioidomycosis." Mycopathologia, 174, p. 353-8
  4. Ampel NM, Robey I, Nguyen CT (2019) "An analysis of skin test responses to spherulin-based coccidioidin (Spherusol) among a group of subjects with various forms of active coccidioidomycosis." Mycopathologia, 184, p. 533-8
  5. Kirkland TN, Hung CY, Shubitz LF, Beyhan S, Fierer J (2024) The host response to coccidioidomycosis. https://www.mdpi.com/2309-608X/10/3/173
  6. Kupers TA, Petrich JM, Holloway AW, St. Geme JW (1970) "Depression of tuberculin delayed hypersensitivity by live attenuated mumps virus." J Pediatr, 76, p. 716-21
  7. Ries F, Alflen A, Aranda Lopez P, et al. (2019) "Antifungal drugs influence neutrophil effector functions." Antimicrob Agents Chemother, 63, e02409-18
  8. Kretschmar M, Geginat G, Bertsch T, Walter S, Hof H, Nichterlein T (2001) "Influence of liposomal amphotericin B on CD8 T-cell function." Antimicrob Agents Chemother, 45, p. 2383-5

Drug and food interactions

Moderate

ketoconazole food

Applies to: ketoconazole

GENERALLY AVOID: Excessive use of alcohol or products containing alcohol together with ketoconazole or levoketoconazole may potentiate the risk of liver injury. Serious hepatotoxicity has been reported with levoketoconazole. Hepatotoxicity requiring liver transplantation has been reported with the use of oral ketoconazole, of which levoketoconazole is an enantiomer. Some patients had no obvious risk factors for liver disease. In addition, use of alcohol or products containing alcohol during ketoconazole or levoketoconazole therapy may result in a disulfiram-like reaction in some patients. Symptoms of disulfiram-like reaction include flushing, rash, peripheral edema, nausea, and headache.

GENERALLY AVOID: Coadministration with grapefruit juice may increase the plasma concentrations of ketoconazole or levoketoconazole. The mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits. Inhibition of hepatic CYP450 3A4 may also contribute. In general, the effect of grapefruit juice is concentration-, dose- and preparation-dependent, and can vary widely among brands. Certain preparations of grapefruit juice (e.g., high dose, double strength) have sometimes demonstrated potent inhibition of CYP450 3A4, while other preparations (e.g., low dose, single strength) have typically demonstrated moderate inhibition. Pharmacokinetic interactions involving grapefruit juice are also subject to a high degree of interpatient variability, thus the extent to which a given patient may be affected is difficult to predict.

When administered to healthy volunteers with a high-fat meal (875 calories; 62% fat), levoketoconazole systemic exposure (AUC) increased by 30% while peak plasma concentration (Cmax) did not change and the time to reach Cmax (Tmax) was delayed from 2 to 4 hours, compared to fasted conditions.

MANAGEMENT: Levoketoconazole may be administered with or without food. Excessive consumption of alcohol should generally be avoided during ketoconazole or levoketoconazole therapy. Patients should preferably avoid or limit consumption of grapefruit, grapefruit juice, or any supplement containing grapefruit extract during ketoconazole or levoketoconazole therapy. Patients receiving ketoconazole or levoketoconazole should be instructed to contact their doctor immediately if they experience swelling, skin rash, itching, loss of appetite, fatigue, nausea, vomiting, abdominal pain, dark colored urine, light colored stools, and/or yellowing of the skin or eyes, as these may be signs and symptoms of liver damage.

References (4)
  1. (2019) "Product Information. Ketoconazole (ketoconazole)." Mylan Pharmaceuticals Inc
  2. (2022) "Product Information. Recorlev (levoketoconazole)." Xeris Pharmaceuticals Inc
  3. Auchus R, Pivonello R, Fleseriu M, et al. (2022) Levoketoconazole: a novel treatment for endogenous Cushing's syndrome. https://www.tandfonline.com/doi/pdf/10.1080/17446651.2021.1945440
  4. (2021) "Product Information. Ketoconazole (ketoconazole)." Burel Pharmaceuticals Inc

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.